188 related articles for article (PubMed ID: 38156860)
41. Programmed death 1 is a marker of angioimmunoblastic T-cell lymphoma and B-cell small lymphocytic lymphoma/chronic lymphocytic leukemia.
Xerri L; Chetaille B; Serriari N; Attias C; Guillaume Y; Arnoulet C; Olive D
Hum Pathol; 2008 Jul; 39(7):1050-8. PubMed ID: 18479731
[TBL] [Abstract][Full Text] [Related]
42. Cyclin D1 expression by histiocytes may mimic cyclin D1-positive proliferation centres of chronic lymphocytic leukaemia/small lymphocytic lymphoma.
Wu J; Zhang Y; Sun L; Zhai Q
Pathol Res Pract; 2018 Jan; 214(1):72-75. PubMed ID: 29254788
[TBL] [Abstract][Full Text] [Related]
43. Diagnosis and prognosis of B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma (B-CLL/SLL) and mantle cell lymphoma (MCL).
Asaad NY; Abd El-Wahed MM; Dawoud MM
J Egypt Natl Canc Inst; 2005 Dec; 17(4):279-90. PubMed ID: 17102815
[TBL] [Abstract][Full Text] [Related]
44. Co-expression of PD-L1 and p-AKT is associated with poor prognosis in diffuse large B-cell lymphoma via PD-1/PD-L1 axis activating intracellular AKT/mTOR pathway in tumor cells.
Dong L; Lv H; Li W; Song Z; Li L; Zhou S; Qiu L; Qian Z; Liu X; Feng L; Meng B; Fu K; Wang X; Pan-Hammarström Q; Wang P; Wang X; Zhang H
Oncotarget; 2016 May; 7(22):33350-62. PubMed ID: 27147575
[TBL] [Abstract][Full Text] [Related]
45. Richter transformation of CLL.
Jain N; Keating MJ
Expert Rev Hematol; 2016 Aug; 9(8):793-801. PubMed ID: 27351634
[TBL] [Abstract][Full Text] [Related]
46. PD-1/PD-L1 Pathway and Its Blockade in Patients with Classic Hodgkin Lymphoma and Non-Hodgkin Large-Cell Lymphomas.
Xie W; Medeiros LJ; Li S; Yin CC; Khoury JD; Xu J
Curr Hematol Malig Rep; 2020 Aug; 15(4):372-381. PubMed ID: 32394185
[TBL] [Abstract][Full Text] [Related]
47. Promoter methylation patterns in Richter syndrome affect stem-cell maintenance and cell cycle regulation and differ from de novo diffuse large B-cell lymphoma.
Rinaldi A; Mensah AA; Kwee I; Forconi F; Orlandi EM; Lucioni M; Gattei V; Marasca R; Berger F; Cogliatti S; Cavalli F; Zucca E; Gaidano G; Rossi D; Bertoni F
Br J Haematol; 2013 Oct; 163(2):194-204. PubMed ID: 23961875
[TBL] [Abstract][Full Text] [Related]
48. Autologous and allogeneic hematopoietic cell transplantation for diffuse large B-cell lymphoma-type Richter syndrome.
Herrera AF; Ahn KW; Litovich C; Chen Y; Assal A; Bashir Q; Bayer RL; Coleman M; DeFilipp Z; Farhadfar N; Greenwood M; Hahn T; Horwitz M; Jacobson C; Jaglowski S; Lachance S; Langston A; Mattar B; Maziarz RT; McGuirk J; Mian MAH; Nathan S; Phillips A; Rakszawski K; Sengeloev H; Shenoy S; Stuart R; Sauter CS; Kharfan-Dabaja MA; Hamadani M
Blood Adv; 2021 Sep; 5(18):3528-3539. PubMed ID: 34496026
[TBL] [Abstract][Full Text] [Related]
49. PD-1 is highly expressed by neoplastic B-cells in Richter transformation.
Behdad A; Griffin B; Chen YH; Ma S; Kelemen K; Lu X; Chen QC
Br J Haematol; 2019 Apr; 185(2):370-373. PubMed ID: 30028010
[No Abstract] [Full Text] [Related]
50. Immunoglobulin somatic hypermutation has clinical impact in DLBCL and potential implications for immune checkpoint blockade and neoantigen-based immunotherapies.
Xu-Monette ZY; Li J; Xia Y; Crossley B; Bremel RD; Miao Y; Xiao M; Snyder T; Manyam GC; Tan X; Zhang H; Visco C; Tzankov A; Dybkaer K; Bhagat G; Tam W; You H; Hsi ED; van Krieken JH; Huh J; Ponzoni M; Ferreri AJM; Møller MB; Piris MA; Winter JN; Medeiros JT; Xu B; Li Y; Kirsch I; Young KH
J Immunother Cancer; 2019 Oct; 7(1):272. PubMed ID: 31640780
[TBL] [Abstract][Full Text] [Related]
51. Clinicopathological analysis of neoplastic PD-L1-positive EBV
Takahara T; Satou A; Ishikawa E; Kohno K; Kato S; Suzuki Y; Takahashi E; Ohashi A; Asano N; Tsuzuki T; Nakamura S
Virchows Arch; 2021 Mar; 478(3):541-552. PubMed ID: 32803453
[TBL] [Abstract][Full Text] [Related]
52. PD-L1 checkpoint blockade prevents immune dysfunction and leukemia development in a mouse model of chronic lymphocytic leukemia.
McClanahan F; Hanna B; Miller S; Clear AJ; Lichter P; Gribben JG; Seiffert M
Blood; 2015 Jul; 126(2):203-11. PubMed ID: 25800048
[TBL] [Abstract][Full Text] [Related]
53. Artificial intelligence strategy integrating morphologic and architectural biomarkers provides robust diagnostic accuracy for disease progression in chronic lymphocytic leukemia.
El Hussein S; Chen P; Medeiros LJ; Wistuba II; Jaffray D; Wu J; Khoury JD
J Pathol; 2022 Jan; 256(1):4-14. PubMed ID: 34505705
[TBL] [Abstract][Full Text] [Related]
54. Secondary CD5+ diffuse large B-cell lymphoma not associated with transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma (Richter syndrome).
Maeshima AM; Taniguchi H; Nomoto J; Maruyama D; Kim SW; Watanabe T; Kobayashi Y; Tobinai K; Matsuno Y
Am J Clin Pathol; 2009 Mar; 131(3):339-46. PubMed ID: 19228640
[TBL] [Abstract][Full Text] [Related]
55. Rare Richter Transformation of Chronic Lymphocytic Lymphoma to Hodgkin Lymphoma.
Buckley T; Inamdar A; Mikhail NH; Loo A; Cohen S
Am J Case Rep; 2021 Dec; 22():e932904. PubMed ID: 34934038
[TBL] [Abstract][Full Text] [Related]
56. Distinct Chemokine Receptor Expression Profiles in De Novo DLBCL, Transformed Follicular Lymphoma, Richter's Trans-Formed DLBCL and Germinal Center B-Cells.
Uhl B; Prochazka KT; Pansy K; Wenzl K; Strobl J; Baumgartner C; Szmyra MM; Waha JE; Wolf A; Tomazic PV; Steinbauer E; Steinwender M; Friedl S; Weniger M; Küppers R; Pichler M; Greinix HT; Stary G; Ramsay AG; Apollonio B; Feichtinger J; Beham-Schmid C; Neumeister P; Deutsch AJ
Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887224
[TBL] [Abstract][Full Text] [Related]
57. Risk factors associated with Richter's transformation in patients with chronic lymphocytic leukaemia: protocol for a retrospective population-based cohort study.
Hleuhel MH; Ben-Dali Y; Da Cunha-Bang C; Brieghel C; Clasen-Linde E; Niemann CU; Andersen MA
BMJ Open; 2019 Mar; 9(3):e023566. PubMed ID: 30833314
[TBL] [Abstract][Full Text] [Related]
58. PD-L1 and tumor-associated macrophages in de novo DLBCL.
McCord R; Bolen CR; Koeppen H; Kadel EE; Oestergaard MZ; Nielsen T; Sehn LH; Venstrom JM
Blood Adv; 2019 Feb; 3(4):531-540. PubMed ID: 30770362
[TBL] [Abstract][Full Text] [Related]
59. Prognostic impact of PD-L1 expression in primary gastric and intestinal diffuse large B-cell lymphoma.
Ishikawa E; Nakamura M; Shimada K; Tanaka T; Satou A; Kohno K; Sakakibara A; Furukawa K; Yamamura T; Miyahara R; Nakamura S; Kato S; Fujishiro M
J Gastroenterol; 2020 Jan; 55(1):39-50. PubMed ID: 31493237
[TBL] [Abstract][Full Text] [Related]
60. Programmed death ligand 1 expression in diffuse large B cell lymphoma: correlation with clinicopathological prognostic factors.
Ibrahim EM; Refat S; El-Ashwah S; Fahmi MW; Ibrahiem AT
J Egypt Natl Canc Inst; 2023 May; 35(1):12. PubMed ID: 37150782
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
